Community hub
Recent from talks
Contribute something to knowledge base
Content stats: 0 posts, 0 articles, 0 media, 0 notes
Members stats: 0 subscribers, 0 contributors, 0 moderators, 0 supporters
Subscribers
Supporters
Contributors
Moderators
Hub AI
Tuberculosis vaccines AI simulator
(@Tuberculosis vaccines_simulator)
Hub AI
Tuberculosis vaccines AI simulator
(@Tuberculosis vaccines_simulator)
Tuberculosis vaccines
Tuberculosis (TB) vaccines are vaccinations intended for the prevention of tuberculosis. Immunotherapy as a defence against TB was first proposed in 1890 by Robert Koch. As of 2021, the only effective tuberculosis vaccine in common use is the Bacillus Calmette-Guérin (BCG) vaccine, first used on humans in 1921. It consists of attenuated (weakened) strains of the cattle tuberculosis bacillus. It is recommended for babies in countries where tuberculosis is common.
About three out of every 10,000 people who get the vaccine experience side effects, which are usually minor except in severely immuno-depressed individuals. While BCG immunization provides fairly effective protection for infants and young children (including defence against TB meningitis and miliary TB), its efficacy in adults is variable, ranging from 0% to 80%. Several variables have been considered as responsible for the varying outcomes. Demand for TB immunotherapy advancement exists because the disease has become increasingly drug-resistant.
Other tuberculosis vaccines are at various stages of development, including:
New vaccines are being developed by the Tuberculosis Vaccine Initiative (TBVI).
To promote successful and lasting management of the TB epidemic, effective vaccination is required. Although the World Health Organization (WHO) endorses a single dose of BCG, revaccination with BCG has been standardized in most, but not all countries. However, improved efficacy of multiple dosages has yet to be demonstrated.
Vaccine development is proceeding along several paths:[citation needed]
Since the BCG vaccine does not offer complete protection against TB, vaccines have been designed to bolster BCG's effectiveness. The industry has now transitioned from developing new alternatives, to selecting the best options currently available to advance into clinical testing. MVA85A was characterized as the "most advanced 'boost' candidate" in 2007. It has since fallen short of its goals.
BCG is currently administered intradermally. To improve efficacy, research approaches have been directed at modifying the delivery method of vaccinations.[citation needed] For example, BCG has much higher protection rates with intravenous injection in monkeys, though some safety questions must be answered before it can be tested on humans.
Tuberculosis vaccines
Tuberculosis (TB) vaccines are vaccinations intended for the prevention of tuberculosis. Immunotherapy as a defence against TB was first proposed in 1890 by Robert Koch. As of 2021, the only effective tuberculosis vaccine in common use is the Bacillus Calmette-Guérin (BCG) vaccine, first used on humans in 1921. It consists of attenuated (weakened) strains of the cattle tuberculosis bacillus. It is recommended for babies in countries where tuberculosis is common.
About three out of every 10,000 people who get the vaccine experience side effects, which are usually minor except in severely immuno-depressed individuals. While BCG immunization provides fairly effective protection for infants and young children (including defence against TB meningitis and miliary TB), its efficacy in adults is variable, ranging from 0% to 80%. Several variables have been considered as responsible for the varying outcomes. Demand for TB immunotherapy advancement exists because the disease has become increasingly drug-resistant.
Other tuberculosis vaccines are at various stages of development, including:
New vaccines are being developed by the Tuberculosis Vaccine Initiative (TBVI).
To promote successful and lasting management of the TB epidemic, effective vaccination is required. Although the World Health Organization (WHO) endorses a single dose of BCG, revaccination with BCG has been standardized in most, but not all countries. However, improved efficacy of multiple dosages has yet to be demonstrated.
Vaccine development is proceeding along several paths:[citation needed]
Since the BCG vaccine does not offer complete protection against TB, vaccines have been designed to bolster BCG's effectiveness. The industry has now transitioned from developing new alternatives, to selecting the best options currently available to advance into clinical testing. MVA85A was characterized as the "most advanced 'boost' candidate" in 2007. It has since fallen short of its goals.
BCG is currently administered intradermally. To improve efficacy, research approaches have been directed at modifying the delivery method of vaccinations.[citation needed] For example, BCG has much higher protection rates with intravenous injection in monkeys, though some safety questions must be answered before it can be tested on humans.